 | • レポートコード：MRC23Q36416 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の体部白癬治療市場について調査・分析し、世界の体部白癬治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（局所、経口）、用途別セグメント分析（病院薬局、小売店薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Perrigo Company、Taro Pharmaceuticals U.S.A., Inc.、Teva Pharmaceuticals, Inc.、Glenmark Pharmaceuticals Inc.、Breckenridge Pharmaceutical, Inc.、NorthStar Rx LLC、Aurobindo Pharma Limited、Camber Pharmaceuticals, Inc.、AvKare, Inc.、Novartis AG、Sebela Pharmaceuticals, Inc.、Bayer AG、Blueberry Therapeutics Ltdなどが含まれています。 世界の体部白癬治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、体部白癬治療市場規模を推定する際に考慮しました。本レポートは、体部白癬治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、体部白癬治療に関するビジネス上の意思決定に役立てることを目的としています。 ・体部白癬治療市場の概要 - 体部白癬治療のタイプ別セグメント - 世界の体部白癬治療市場規模：タイプ別分析（局所、経口） - 体部白癬治療の用途別セグメント - 世界の体部白癬治療市場規模：用途別分析（病院薬局、小売店薬局、その他） - 世界の体部白癬治療市場規模予測（2018年-2029年） ・体部白癬治療市場の成長トレンド - 体部白癬治療の地域別市場規模（2018年-2029年） - 体部白癬治療市場ダイナミクス - 体部白癬治療の業界動向 - 体部白癬治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：局所、経口 - 世界の体部白癬治療のタイプ別市場規模（2018年-2023年） - 世界の体部白癬治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院薬局、小売店薬局、その他 - 世界の体部白癬治療の用途別市場規模（2018年-2023年） - 世界の体部白癬治療の用途別市場規模（2024年-2029年） ・体部白癬治療の地域別市場規模 - 北米の体部白癬治療市場規模（2018年-2029年） - アメリカの体部白癬治療市場規模（2018年-2029年） - ヨーロッパの体部白癬治療市場規模（2018年-2029年） - アジア太平洋の体部白癬治療市場規模（2018年-2029年） - 中国の体部白癬治療市場規模（2018年-2029年） - 日本の体部白癬治療市場規模（2018年-2029年） - 韓国の体部白癬治療市場規模（2018年-2029年） - インドの体部白癬治療市場規模（2018年-2029年） - オーストラリアの体部白癬治療市場規模（2018年-2029年） - 中南米の体部白癬治療市場規模（2018年-2029年） - 中東・アフリカの体部白癬治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Perrigo Company、Taro Pharmaceuticals U.S.A., Inc.、Teva Pharmaceuticals, Inc.、Glenmark Pharmaceuticals Inc.、Breckenridge Pharmaceutical, Inc.、NorthStar Rx LLC、Aurobindo Pharma Limited、Camber Pharmaceuticals, Inc.、AvKare, Inc.、Novartis AG、Sebela Pharmaceuticals, Inc.、Bayer AG、Blueberry Therapeutics Ltd ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Tinea Corporis Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Tinea Corporis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Tinea Corporis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Tinea Corporis Treatment in Hospital Pharmacy is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Tinea Corporis Treatment include Perrigo Company, Taro Pharmaceuticals U.S.A., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc., Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Limited, Camber Pharmaceuticals, Inc. and AvKare, Inc., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tinea Corporis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tinea Corporis Treatment.
The Tinea Corporis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Tinea Corporis Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tinea Corporis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Perrigo Company
Taro Pharmaceuticals U.S.A., Inc.
Teva Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Inc.
Breckenridge Pharmaceutical, Inc.
NorthStar Rx LLC
Aurobindo Pharma Limited
Camber Pharmaceuticals, Inc.
AvKare, Inc.
Novartis AG
Sebela Pharmaceuticals, Inc.
Bayer AG
Blueberry Therapeutics Ltd
Segment by Type
Topical
Oral
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tinea Corporis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tinea Corporis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Topical
1.2.3 Oral
1.3 Market by Application
1.3.1 Global Tinea Corporis Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tinea Corporis Treatment Market Perspective (2018-2029)
2.2 Tinea Corporis Treatment Growth Trends by Region
2.2.1 Global Tinea Corporis Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tinea Corporis Treatment Historic Market Size by Region (2018-2023)
2.2.3 Tinea Corporis Treatment Forecasted Market Size by Region (2024-2029)
2.3 Tinea Corporis Treatment Market Dynamics
2.3.1 Tinea Corporis Treatment Industry Trends
2.3.2 Tinea Corporis Treatment Market Drivers
2.3.3 Tinea Corporis Treatment Market Challenges
2.3.4 Tinea Corporis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tinea Corporis Treatment Players by Revenue
3.1.1 Global Top Tinea Corporis Treatment Players by Revenue (2018-2023)
3.1.2 Global Tinea Corporis Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Tinea Corporis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tinea Corporis Treatment Revenue
3.4 Global Tinea Corporis Treatment Market Concentration Ratio
3.4.1 Global Tinea Corporis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tinea Corporis Treatment Revenue in 2022
3.5 Tinea Corporis Treatment Key Players Head office and Area Served
3.6 Key Players Tinea Corporis Treatment Product Solution and Service
3.7 Date of Enter into Tinea Corporis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tinea Corporis Treatment Breakdown Data by Type
4.1 Global Tinea Corporis Treatment Historic Market Size by Type (2018-2023)
4.2 Global Tinea Corporis Treatment Forecasted Market Size by Type (2024-2029)
5 Tinea Corporis Treatment Breakdown Data by Application
5.1 Global Tinea Corporis Treatment Historic Market Size by Application (2018-2023)
5.2 Global Tinea Corporis Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Tinea Corporis Treatment Market Size (2018-2029)
6.2 North America Tinea Corporis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tinea Corporis Treatment Market Size by Country (2018-2023)
6.4 North America Tinea Corporis Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tinea Corporis Treatment Market Size (2018-2029)
7.2 Europe Tinea Corporis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tinea Corporis Treatment Market Size by Country (2018-2023)
7.4 Europe Tinea Corporis Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tinea Corporis Treatment Market Size (2018-2029)
8.2 Asia-Pacific Tinea Corporis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tinea Corporis Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Tinea Corporis Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tinea Corporis Treatment Market Size (2018-2029)
9.2 Latin America Tinea Corporis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tinea Corporis Treatment Market Size by Country (2018-2023)
9.4 Latin America Tinea Corporis Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tinea Corporis Treatment Market Size (2018-2029)
10.2 Middle East & Africa Tinea Corporis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tinea Corporis Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Tinea Corporis Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Perrigo Company
11.1.1 Perrigo Company Company Detail
11.1.2 Perrigo Company Business Overview
11.1.3 Perrigo Company Tinea Corporis Treatment Introduction
11.1.4 Perrigo Company Revenue in Tinea Corporis Treatment Business (2018-2023)
11.1.5 Perrigo Company Recent Development
11.2 Taro Pharmaceuticals U.S.A., Inc.
11.2.1 Taro Pharmaceuticals U.S.A., Inc. Company Detail
11.2.2 Taro Pharmaceuticals U.S.A., Inc. Business Overview
11.2.3 Taro Pharmaceuticals U.S.A., Inc. Tinea Corporis Treatment Introduction
11.2.4 Taro Pharmaceuticals U.S.A., Inc. Revenue in Tinea Corporis Treatment Business (2018-2023)
11.2.5 Taro Pharmaceuticals U.S.A., Inc. Recent Development
11.3 Teva Pharmaceuticals, Inc.
11.3.1 Teva Pharmaceuticals, Inc. Company Detail
11.3.2 Teva Pharmaceuticals, Inc. Business Overview
11.3.3 Teva Pharmaceuticals, Inc. Tinea Corporis Treatment Introduction
11.3.4 Teva Pharmaceuticals, Inc. Revenue in Tinea Corporis Treatment Business (2018-2023)
11.3.5 Teva Pharmaceuticals, Inc. Recent Development
11.4 Glenmark Pharmaceuticals Inc.
11.4.1 Glenmark Pharmaceuticals Inc. Company Detail
11.4.2 Glenmark Pharmaceuticals Inc. Business Overview
11.4.3 Glenmark Pharmaceuticals Inc. Tinea Corporis Treatment Introduction
11.4.4 Glenmark Pharmaceuticals Inc. Revenue in Tinea Corporis Treatment Business (2018-2023)
11.4.5 Glenmark Pharmaceuticals Inc. Recent Development
11.5 Breckenridge Pharmaceutical, Inc.
11.5.1 Breckenridge Pharmaceutical, Inc. Company Detail
11.5.2 Breckenridge Pharmaceutical, Inc. Business Overview
11.5.3 Breckenridge Pharmaceutical, Inc. Tinea Corporis Treatment Introduction
11.5.4 Breckenridge Pharmaceutical, Inc. Revenue in Tinea Corporis Treatment Business (2018-2023)
11.5.5 Breckenridge Pharmaceutical, Inc. Recent Development
11.6 NorthStar Rx LLC
11.6.1 NorthStar Rx LLC Company Detail
11.6.2 NorthStar Rx LLC Business Overview
11.6.3 NorthStar Rx LLC Tinea Corporis Treatment Introduction
11.6.4 NorthStar Rx LLC Revenue in Tinea Corporis Treatment Business (2018-2023)
11.6.5 NorthStar Rx LLC Recent Development
11.7 Aurobindo Pharma Limited
11.7.1 Aurobindo Pharma Limited Company Detail
11.7.2 Aurobindo Pharma Limited Business Overview
11.7.3 Aurobindo Pharma Limited Tinea Corporis Treatment Introduction
11.7.4 Aurobindo Pharma Limited Revenue in Tinea Corporis Treatment Business (2018-2023)
11.7.5 Aurobindo Pharma Limited Recent Development
11.8 Camber Pharmaceuticals, Inc.
11.8.1 Camber Pharmaceuticals, Inc. Company Detail
11.8.2 Camber Pharmaceuticals, Inc. Business Overview
11.8.3 Camber Pharmaceuticals, Inc. Tinea Corporis Treatment Introduction
11.8.4 Camber Pharmaceuticals, Inc. Revenue in Tinea Corporis Treatment Business (2018-2023)
11.8.5 Camber Pharmaceuticals, Inc. Recent Development
11.9 AvKare, Inc.
11.9.1 AvKare, Inc. Company Detail
11.9.2 AvKare, Inc. Business Overview
11.9.3 AvKare, Inc. Tinea Corporis Treatment Introduction
11.9.4 AvKare, Inc. Revenue in Tinea Corporis Treatment Business (2018-2023)
11.9.5 AvKare, Inc. Recent Development
11.10 Novartis AG
11.10.1 Novartis AG Company Detail
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG Tinea Corporis Treatment Introduction
11.10.4 Novartis AG Revenue in Tinea Corporis Treatment Business (2018-2023)
11.10.5 Novartis AG Recent Development
11.11 Sebela Pharmaceuticals, Inc.
11.11.1 Sebela Pharmaceuticals, Inc. Company Detail
11.11.2 Sebela Pharmaceuticals, Inc. Business Overview
11.11.3 Sebela Pharmaceuticals, Inc. Tinea Corporis Treatment Introduction
11.11.4 Sebela Pharmaceuticals, Inc. Revenue in Tinea Corporis Treatment Business (2018-2023)
11.11.5 Sebela Pharmaceuticals, Inc. Recent Development
11.12 Bayer AG
11.12.1 Bayer AG Company Detail
11.12.2 Bayer AG Business Overview
11.12.3 Bayer AG Tinea Corporis Treatment Introduction
11.12.4 Bayer AG Revenue in Tinea Corporis Treatment Business (2018-2023)
11.12.5 Bayer AG Recent Development
11.13 Blueberry Therapeutics Ltd
11.13.1 Blueberry Therapeutics Ltd Company Detail
11.13.2 Blueberry Therapeutics Ltd Business Overview
11.13.3 Blueberry Therapeutics Ltd Tinea Corporis Treatment Introduction
11.13.4 Blueberry Therapeutics Ltd Revenue in Tinea Corporis Treatment Business (2018-2023)
11.13.5 Blueberry Therapeutics Ltd Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details